Iopromide is a nonionic, low-osmolality iodinated contrast agent widely used in diagnostic imaging to enhance the visibility of blood vessels, organs, and tissues during X-ray and CT procedures. It was developed in the 1980s as part of efforts to create safer contrast media with reduced risk of adverse reactions compared to older, high-osmolality ionic agents. Its nonionic structure contributes to lower osmolality, improving patient tolerability and minimizing discomfort during administration. Iopromide can be used for intravascular, intra-arterial, intrathecal, and urinary tract imaging, making it highly versatile in clinical practice. The agent rapidly distributes in the vascular system and is primarily excreted unchanged by the kidneys. Its development marked a significant improvement in contrast media safety and imaging quality. Iopromide has been extensively tested in clinical trials to ensure efficacy and minimize potential side effects. It is particularly valued for cardiovascular, neurological, and urinary tract imaging. Over the years, it has become one of the preferred contrast agents in modern radiology. Today, iopromide continues to be widely used due to its safety, effectiveness, and broad applicability in diagnostic imaging.
